The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Offer details
Expected size of offer (M): 4.7m
Expected first date of trading: 27/08/2014
Market: AIM
Location of address at which admission document will be available: The admission document containing full details about Medaphor and the admission of its ordinary shares will be available from the registered office of Medaphor, being Cardiff Medicentre, Heath Park, Cardiff,CF14 4UJ, Wales UK
Date at which admission document will be available: -

Advisors
Sponsor: -
Nominated Advisor (AIM Companies): Cenkos Securities plc
Nominated Broker (AIM Companies): Cenkos Securities plc

Company details
Name Role
Riccardo Pigliucci Non-Executive Chairman
Stuart Gall Chief Executive Officer
Nicholas Sleep Chief Technology Officer
Wilson Jennings Finance Director
Professor Nazar Amso Medical Director (Non-Executive Director)
David Baynes Non-Executive Director
Professor Nick Avis Non-Executive Director

Facts and Figures
Fiscal year end: 31 December
Incorporated in: UK
Website URL: http://www.medaphor.com/
space
Description of business:
Medaphor is a global provider of advanced ultrasound education and training simulators for medical professionals. Medaphor's lead product is the ScanTrainer ultrasound simulator training platform. The Company is based in Cardiff in the UK and San Diego in the USA. The ScanTrainer simulator assists students, doctors and sonographers to acquire ultrasound scanning skills, with minimal expert...

Person(s) interested:
Prior to Admission IP Group plc - 46.1% (1)(2) Finance Wales Investments (5) Limited - 17.4% Finance Wales Investments (6) Limited - 14.1% Professor Nazar Amso - 9.1% (3) Peter Gill - 6.3% (1) IP Group plc's interests in the Ordinary Shares prior to Admission is split between Fusion IP Cardiff Limited (3,188,000 Ordinary Shares), IP2 IPO Limited (918,000 Ordinary Shares) and funds managed by IP Venture Fund II (394,000 Ordinary Shares). David Baynes, a Non-Executive Director, of the Company is a director of IP Group plc and therefore has a non-beneficial interest in the Ordinary Shares held by IP Group plc. (2) IP Group plc is also interested in 1,000,000 A Shares, which represents 100% of the A Shares. On Admission, the A Shares convert into Ordinary Shares. (3) Nazar Amso's interest in Ordinary Shares prior to Admission is split between his direct holding of 624,000 Ordinary Shares, the Amso Trust's holding of 180,000 Ordinary Shares and his wife's holding of 80,000 Ordinary Shares. Post Admission IP Group plc - 47.2% (1) Finance Wales Investments (6) Limited - 14.6% Finance Wales Investments (5) Limited - 8.5% Professor Nazar Amso - 6.9% (2) Arthurian Life Sciences Limited - 6.0% Sand Aire Limited - 4.0% Peter Gill - 3.1% (1) IP Group's interests in the Ordinary Shares prior to Admission is split between Fusion IP Cardiff Limited's holding of 3,188,000 Ordinary Shares, IP2IPO Limited's holding of 918,000 Ordinary Shares and the holding of IP Venture Fund II LP, a fund managed by Top Technology Ventures Limited (a wholly owned subsidiary of IP Group plc), being 394,000 Ordinary Shares. IP Group's interest in A Shares is held by Fusion IP Cardiff Limited. On Admission, the A Shares will convert into Ordinary Shares and there will thereafter be no A Shares in issue. Following Admission, IP Group's interests in the Ordinary Shares will be split between Fusion IP Cardiff Limited's holding of 4,388,000 Ordinary Shares, IP2IPO Limited's holding of 3,578,000 Ordinary Shares and IP Venture Fund II LP's holding of 1,534,000 Ordinary Shares. (2) Nazar Amso's interest in Ordinary Shares prior to Admission is split between his direct holding of 624,000 Ordinary Shares, the Amso Trust's holding of 180,000 Ordinary Shares and his wife's holding of 80,000 Ordinary Shares. Nazar Amso's interest in Ordinary Shares following Admission is split between his direct holding of 1,084,000 Ordinary Shares, the Amso Trusts holding of 180,000 Ordinary Shares and his wife's holding of 120,000 Ordinary Shares.


Medaphor Group plc

Related links

Further informations about 7 and 7/30 days issues can be find by clicking on one of the options below:

Issues last 7 days

Last issues 7/30 days

Back to New and recent issues - Home



The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds